Pharma BD Deal Intelligence
Incivo/Incivek was a real launch success for two years, then was obsoleted almost overnight by all-oral DAAs — J&J bought out Vertex's royalty in 2013 near the top and still withdrew the drug from Europe by 2016.
Full analysis, sources & comparables →SEC filing exhibit confirms the Vertex-Tibotec collaboration terms, including territorial split (Vertex NA + Far East via Mitsubishi; Janssen ex-NA, ex-Far…
Telaprevir achieved 69-75% SVR vs 44% control in genotype 1 treatment-naive patients; FDA approval was unanimous (18-0) in April 2011 with full approval May…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
HCV; $165M upfront + up to $380M milestones; Tibotec/Janssen got ex-NA, ex-Far East rights
Incivo/Incivek was a real launch success for two years, then was obsoleted almost overnight by all-oral DAAs — J&J bought out Vertex's royalty in 2013 near the top and still withdrew the drug from Europe by 2016.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Vertex Pharmaceuticals (telaprevir ex-NA/ex-Far East rights) (this deal) | 2006 | $545M | 49 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2006 deals · Johnson & Johnson deals · Infectious Disease deals